All In Biotech

Drug Trial Radar · NCT01074294

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Feb 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

740

Actual

Start

Mar 16, 2010

Primary completion

Jun 20, 2011

Study completion Jun 20, 2011

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact on sleep, quality of life and cognitive function.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

  • OPDC-34712Drug

    OPDC-34712 tablets, daily, Orally.

  • PlaceboDrug

    Matching-placebo tablets, daily, Orally.

  • Stimulant TherapyDrug

    Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase BTime frame: Baseline [end of Phase A (Week 5)] to Week 11

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Beverly Hills, California

  • Site not named

    Irvine, California

  • Site not named

    Pasadena, California

  • Site not named

    San Francisco, California

  • Site not named

    Bradenton, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Maitland, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    South Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Overland Park, Kansas

  • Site not named

    Rochester Hills, Michigan

  • Site not named

    Saint Charles, Missouri

  • Site not named

    Cherry Hill, New Jersey

  • Site not named

    Willingboro, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Memphis, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Woodstock, Vermont

  • Site not named

    Herndon, Virginia

  • Site not named

    Bellevue, Washington

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.